611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA
Amended material disclosure
Reverse Stock Split Approved at 1-for-20 Ratio by Quince Therapeutics
Election of Director - June Bray Approved by Stockholders
Other Events
Annual Report to Security Holders
Appointment of June Bray to Quince Therapeutics Board of Directors
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload